251 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
for PARP inhibitor therapy. HRD status is determined using two independent methods: BRCA1 and BRCA2 status that encompasses sequence variants and large … , or, if none apply, an amount determined by an independent dispute resolution entity. The cost-sharing amount is limited to an amount determined
8-K
EX-99.1
x09ybjy70f
16 Jan 24
Results of Operations and Financial Condition
9:00am
8-K
EX-1.1
38kzjf8qiyuk9
13 Nov 23
Entry into a Material Definitive Agreement
4:31pm
424B5
1eads duq2lmn0
13 Nov 23
Prospectus supplement for primary offering
6:02am
424B5
0cvz6ex11rdf4
8 Nov 23
Prospectus supplement for primary offering
4:05pm
S-3ASR
ladgydv3 fr4s42w1na
8 Nov 23
Automatic shelf registration
4:01pm
S-3ASR
EX-4.3
uhlfs8foh
8 Nov 23
Automatic shelf registration
4:01pm
S-3ASR
EX-23.1
0wgv6dscd0jz4y75
8 Nov 23
Automatic shelf registration
4:01pm
8-K
EX-10.1
ozsedqh vmn
5 Oct 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
f7ya933 2f8
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-10.2
wacog08y1q0lnis
6 Jul 23
Entry into a Material Definitive Agreement
8:24am
8-K
EX-10.1
6aqx r9evt
6 Jul 23
Entry into a Material Definitive Agreement
8:24am
8-K
q1iec137a85qva9yvfd
2 Jun 23
Departure of Directors or Certain Officers
4:31pm